Sangamo Soars as Hemophilia Gene Therapy Results Quiet Bears
Red blood cells form a clot.
Source: Image Source/Getty Images
This article is for subscribers only.
Sangamo Therapeutics Inc. soared after encouraging results from an early study of its hemophilia A gene therapy impressed bulls and quieted skeptics.
The small-cap biotech and its partner Pfizer Inc. reported that patients receiving the medicine, known as SB-525, saw an increase in the blood-clotting protein factor VIII that topped some expectations. Six weeks after infusion, patients receiving the highest dose reached factor VIII levels that were 140 percent and 94 percent of normal, as measured by a clotting assay.